natgillin/translations-raw huggingface dataset:
Flolan is contraindicated in patients: • with known hypersensitivity to the active substance(s) or to any of the excipients listed in section
Zdravilo Flolan je kontraindicirano pri bolnikih: • z znano preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju
METHOD AND ROUTE(S) OF ADMINISTRATION The powder needs to be reconstituted and diluted before infusion.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Prašek je treba pred infundiranjem pripraviti in razredčiti.
General Disorders and Administration Site Conditions Very common Pain (unspecified) Common
Splošne težave in spremembe na mestu aplikacije Zelo pogosti bolečina (neopredeljena)
The infusion rate should be increased by 1 to 2 nanograms/kg/min increments at intervals sufficient to allow assessment of clinical response; these intervals should be of at least 15 min.
Hitrost infundiranja je treba povečevati po 1 do 2 nanograma/kg/min v presledkih, ki zadoščajo za oceno kliničnega odziva; ti presledki morajo trajati vsaj 15 minut.
Epoprostenol is only indicated for continuous infusion by intravenous route.
Epoprostenol je indiciran le za stalno intravensko infundiranje.
Visible clotting (not necessitating intervention) was reported in another 31% of epoprostenol dialyses and 5% of heparin dialyses.
Vidno strjevanje (ki ni zahtevalo ukrepanja) so zabeležili pri dodatnih 31 % dializ z epoprostenolom in 5 % dializ s heparinom.
• pale skin
• bleda koža,
Common side effects that may show up in blood tests • decrease in the number of blood platelets (cells that help the blood to clot)
Pogosti neželeni učinki, ki se lahko pokažejo pri preiskavah krvi • zmanjšanje števila krvnih ploščic (trombocitov; to so celice, ki sodelujejo pri strjevanju krvi).
Effects on platelets have been found to disappear within 2 hours of discontinuing the infusion, and haemodynamic changes due to epoprostenol to return to baseline within 10 minutes of termination of 60 minutes infusion at 1 to 16 nanograms/kg/min.
Ugotovljeno je, da učinki na trombocite izginejo v 2 urah po koncu infundiranja, hemodinamske spremembe zaradi epoprostenola pa se vrnejo na izhodiščne vrednosti v 10 minutah po koncu 60-minutnega infundiranja od 1 do 16 nanogramov/kg/min.
There are no data regarding the effect of Flolan used in renal dialysis on the ability to drive or operate machinery.
Podatkov o vplivu zdravila Flolan, uporabljenega pri ledvični dializi, na sposobnost vožnje in upravljanja s stroji ni.
Keep container in the outer carton to protect from light.
Vsebnik shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Very rare
Zelo redki bledica
• stomach discomfort or pain
• nelagodje ali bolečine v želodcu,
Epoprostenol must not be administered as a bolus injection
Epoprostenola se ne sme dajati v bolusni injekciji.
Flolan is used to prevent blood clotting during kidney dialysis when heparin cannot be used.
Zdravilo Flolan se uporablja za preprečevanje krvnih strdkov med ledvično dializo, kadar ni mogoče uporabiti heparina.
Reconstitution, dilution and calculation of infusion rate:
Priprava, razredčenje in izračun hitrosti infundiranja:
Flolan may either decrease or increase heart rate.
Zdravilo Flolan lahko poveča ali zmanjša srčno frekvenco.
Infusion rate formulae - examples
Formule - primeri za hitrost infundiranja
If you are being given Flolan using an infusion pump, a ‘cold pouch' may be used to maintain the temperature of the solution.
Če zdravilo Flolan prejemate z infuzijsko črpalko, lahko za vzdrževanje temperature raztopine uporabite "hladno vrečko".
Stopping Flolan must be done gradually.
Prenehanje uporabe zdravila Flolan mora biti opravljeno postopoma.
Sodium Hydroxide (for pH adjustment)
Natrijev hidroksid (za prilagoditev pH)
Preparation of Flolan intravenous injectable solution:
Priprava raztopine Flolan za intravensko injiciranje:
For administration using a pump capable of delivering small volume constant infusions, suitable aliquots of concentrated solution may be diluted with sterile sodium chloride 0.9% w/v solution.
Za uporabo s črpalko, ki lahko daje majhno stalno količino infuzije, je treba ustrezne alikvote koncentrirane raztopine razredčiti s sterilno 0,9 % (m/v) raztopino natrijevega klorida.
The decision to administer Flolan for pulmonary arterial hypertension should be based upon the patient's understanding that there is a high likelihood that therapy with Flolan will be needed for prolonged periods, possibly years, and the patient's ability to accept and care for a permanent i.v.
Odločitev za uporabo zdravila Flolan pri pljučni arterijski hipertenziji mora temeljiti na bolnikovem razumevanju, da bo zdravljenje zelo verjetno potrebno dolgo časa, morda leta, in bolnikovo zmožnostjo, da sprejme in skrbi za stalni intravenski kateter ter infuzijsko črpalko.
Flolan is a potent pulmonary and systemic vasodilator.
Zdravilo Flolan je močan pljučni in sistemski vazodilatator.
It may be diluted with sodium chloride 0.9% w/v solution, provided a ratio of 6 volumes of sodium chloride 0.9% w/v solution to 1 volume of concentrated solution is not exceeded e.g. 50 mL of concentrated solution further diluted with a maximum of 300 mL sodium chloride 0.9% w/v solution.
Razredčiti jo je mogoče z 0,9 % (m/v) raztopino natrijevega klorida, pod pogojem, da ni preseženo razmerje 6 delov 0,9 % (m/v) raztopine natrijevega klorida na 1 del koncentrirane raztopine, npr. 50 ml koncentrirane raztopine, nadalje razredčene z največ 300 ml 0,9 % (m/v) raztopine natrijevega klorida.
Intravenous epoprostenol infusions of up to 15 minutes have been found to produce dose-related increases in cardiac index (CI) and stroke volume (SV), and dose-related decreases in pulmonary vascular resistance (PVR), total pulmonary resistance (TPR) and mean systemic arterial pressure (SAPm).
Do 15-minutno intravensko infundiranje epoprostenola povzroči od odmerka odvisno povečanje srčnega indeksa (CI - cardiac index) in utripnega volumna (SV - stroke volume) ter od odmerka odvisno zmanjšanje pljučnega žilnega upora (PVR - pulmonary vascular resistance), celotnega pljučnega upora (TPR - total pulmonary resistance) in srednjega sistemskega arterijskega tlaka (SAPm - mean systemic arterial pressure).
Flolan widens the blood vessels to lower the blood pressure in the lungs.
Zdravilo Flolan razširi žile in tako zniža krvni tlak v pljučih.
Freshly prepared epoprostenol solutions for the treatment of pulmonary arterial hypertension should be used within 12 hours at 25°C, or stored for up to 40 hours at between 2 to 8°C and then used within 8 hours at
Sveže pripravljeno raztopino epoprostenola za zdravljenje pljučne arterijske hipertenzije je treba uporabiti v 12 urah pri temperaturi 25 °C, lahko pa se jo do 40 ur hrani pri temperaturi od 2 do 8 °C in nato uporabi v 8 urah pri temperaturi 25 °C.
Sodium Hydroxide (for pH adjustment) Water for Injection
Natrijev hidroksid (za prilagoditev pH) Voda za injekcije
If you have been fitted with a ‘line' into a vein it is very important to keep this area clean, otherwise you could get an infection.
Zato je zelo pomembno, da ohranjate to mesto čisto, ker se vam sicer lahko pojavi okužba.
Skin damage at the injection site
Poškodba kože na mestu injiciranja
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for parenteral use for Flolan
IME ZDRAVILA IN POT(I) UPORABE Vehikel za parenteralno uporabo za zdravilo Flolan intravenska uporaba
Reconstituted solutions, prepared in real time, must not be administered over more than 12 hours when they are used at room temperature (between 15°C and 25°C).
Pripravljene raztopine, pripravljene v realnem času, se ne sme dajati več kot 12 ur, če je uporabljena pri sobni temperaturi (med 15 in 25 °C).
This SmPC, labelling and package leaflet is the version valid at the time of Commission decision.
Opomba: Ta različica povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je različica, ki je v veljavi v času sprejema odločbe Komisije.
Sixteen patients received 24 epoprostenol dialyses in emergency studies.
V urgentnih študijah je 16 bolnikov prejelo 24 dializ z epoprostenolom.
Endocrine Disorders
Bolezni endokrinega sistema
Initially a pack containing solvent for parenteral use must be used.
Uvodoma je treba uporabiti pakiranje, ki vsebuje vehikel za parenteralno uporabo.
When used in renal dialysis Flolan may be administered as the concentrated solution (a) or in diluted form (b).
Med uporabo pri ledvični dializi se lahko zdravilo Flolan daje kot koncentrirana raztopina (a) ali v razredčeni obliki (b).
Very common Facial flushing (seen even in the anaesthetised patient) Common
Žilne bolezni Zelo pogosti zardevanje obraza (opazno celo pri anesteziranih bolnikih)
• build up of fluid in the lungs (pulmonary oedema)
• kopičenje tekočine v pljučih (pljučni edem),
To dilute the concentrated solution, draw it up into a larger syringe and then attach the sterile filter provided to the syringe.
Za razredčenje koncentrirane raztopine jo izvlecite v večjo brizgo in nato namestite priloženi sterilni filter.
Flolan is infused continuously through a permanent indwelling central venous catheter via a small, portable infusion pump.
Zdravilo Flolan se infundira v stalni infuziji po stalnem centralnem venskem katetru z majhno, prenosno infuzijsko črpalko.
Flolan has been successfully used instead of heparin in renal dialysis but in a small proportion of dialyses clotting has developed in the dialysis circuit, requiring termination of dialysis.
Zdravilo Flolan so pri ledvični dializi uspešno uporabljali namesto heparina, a pri majhnem deležu bolnikov je prišlo do strjevanja v dializnem obtoku, tako da je bilo treba z dializo prenehati.
4.7 Effects on ability to drive and use machines Pulmonary arterial hypertension and its therapeutic management may affect the ability to drive and operate machinery.
Pljučna arterijska hipertenzija in njeno terapevtsko obvladovanje lahko vplivata na sposobnost vožnje in upravljanja s stroji.
Pulmonary Arterial Hypertension Some patients with pulmonary arterial hypertension have developed pulmonary oedema during doseranging, which may be associated with pulmonary veno-occlusive disease.
Nekaterim bolnikom s pljučno arterijsko hipertenzijo se je med ugotavljanjem odmerka razvil pljučni edem, ki je lahko povezan s pljučno vensko okluzivno boleznijo.
The amount of sodium present in the powder for solution for infusion equals 2.7 mg approximately per vial.
Količina natrija v prašku za raztopino za infundiranje je približno 2,7 mg na vialo.
Some medicines may affect how Flolan works, or make it more likely that you'll have side effects.
Nekatera zdravila lahko vplivajo na delovanje zdravila Flolan ali povečajo verjetnost za pojav neželenih učinkov.
When NSAIDS or other drugs affecting platelet aggregation are used concomitantly, there is the potential for Flolan to increase the risk of bleeding.
Med sočasno uporabo nesteroidnih protivnetnih zdravil (NSPVZ) ali drugih zdravil, ki vplivajo na agregacijo trombocitov, lahko zdravilo Flolan poveča tveganje za krvavitve.
If the maximum tolerated infusion rate is less than 5 nanograms/kg/min, the long-term infusion should be started at one-half the maximum tolerated infusion rate.
Če je največja tolerirana hitrost infundiranja manjša od 5 nanogramov/kg/min, je treba dolgotrajno infundiranje začeti s polovično največjo tolerirano hitrostjo infundiranja.
OTHER SPECIAL WARNING(S), IF NECESSARY Use as directed by your physician EXPIRY DATE
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Uporabljajte po zdravnikovih navodilih.
Therefore, this SmPC, labelling and package leaflet may not necessarily represent the current text.
Tako ta povzetek glavnih značilnosti zdravila, označevanja in navodilo za uporabo morda ne odražajo trenutnega besedila.
The filter must be used once only and then discarded.
Filter se sme uporabiti samo enkrat in ga je potem treba zavreči.
Major clotting (dialysis permanently suspended, or requiring changing of artificial kidney) occurred in approximately 9% (n=56) of all epoprostenol dialyses and in <1% (n=1) of heparin dialyses in major controlled studies and emergency studies.
Pomembno strjevanje (trajna prekinitev dialize ali potreba po menjavi umetne ledvice) se je v večjih kontroliranih študijah in urgentnih študijah pojavilo pri približno 9 % (n = 56) vseh dializ z epoprostenolom in pri < 1 % (n = 1) dializ s heparinom.
The primary efficacy endpoint for the study was improvement in the 6MWT.
Primarni opazovani dogodek v študiji je bilo izboljšanje 6-minutnega testa hoje.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.
Če imate kakšna dodatna vprašanja o uporabi tega zdravila, se obrnite na svojega zdravnika, farmacevta ali medicinsko sestro.
Epoprostenol Sodium, the monosodium salt of epoprostenol, a naturally occurring prostaglandin produced by the intima of blood vessels.
Natrijev epoprostenolat, mononatrijeva sol epoprostenola, je naraven prostaglandin, ki nastaja v žilni intimi.
Not all pack sizes are available in all markets.
Na trgu morda ni vseh navedenih pakiranj.
Calculation of infusion rate:
Izračun hitrosti infundiranja:
The infusion rate may be calculated from the formula given above for renal dialysis.
Hitrost infundiranja je mogoče izračunati po formuli za ledvično dializo, navedeni zgoraj.
Reconstituted solutions must not be administered over more than 12 hours when they are used at room temperature (between 15°C and 25°C).
Pripravljene raztopine se ne sme dajati več kot 12 ur, če je uporabljena pri sobni temperaturi (med 15 in 25 °C).
Flolan is used to treat a lung condition called ‘pulmonary arterial hypertension'.
Zdravilo Flolan se uporablja za zdravljenje pljučne bolezni, imenovane "pljučna arterijska hipertenzija".
When using a ‘cold pouch', the solution can be stored in the pump for up to 24 hours at 2-8oC if necessary.
Med uporabo "hladne vrečke" je mogoče raztopino shranjevati v črpalki do 24 ur pri temperaturi od 2 do 8 oC, če je treba.
Flolan is a solution for injection made up of powder and solution.
Zdravilo Flolan je raztopina za injiciranje, pripravljena iz praška in raztopine.
Concentrations commonly used in the treatment pulmonary arterial hypertension are as follows:
Koncentracije, ki se pogosto uporabljajo pri zdravljenju pljučne arterijske hipertenzije, so:
The filter unit must be used once only and then discarded.
Filtrirno enoto se sme uporabiti samo enkrat in jo je potem treba zavreči.
Intravenous use Read the package leaflet before use.
intravenska uporaba Pred uporabo preberite priloženo navodilo!
Flolan comes as a powder in a glass vial.
Zdravilo Flolan je na voljo kot prašek v stekleni viali.
Bleeding severity worsened during only 1 dialysis day with epoprostenol (N=1/16) whereas severity worsened during 5 dialysis days (N=5/25) and 2 predialysis days (N=2/13) with heparin.
Izrazitost krvavitev se je z epoprostenolom poslabšala le med 1 dializnim dnevom (n = 1/16), s heparinom pa se je poslabšala med 5 dializnimi dnevi (n = 5/25) in 2 preddializnima dnevoma (n = 2/13).
The amount of sodium present in the solvent for parenteral use equals 53.2 mg approximately per vial.
Količina natrija v vehiklu za parenteralno uporabo je približno 53,2 mg na vialo.
Flolan contains the active substance epoprostenol which belongs to a group of medicines called prostaglandin, which stops blood from clotting and widens the blood vessels.
Epoprostenol spada v skupino zdravil, imenovanih prostaglandini; ta zdravila preprečijo strjevanje krvi in razširijo žile.
What Flolan looks like and contents of the pack
Izgled zdravila Flolan in vsebina pakiranja
Flolan is given by slow infusion (drip) into a vein.
Zdravilo Flolan se daje s počasno infuzijo (kapalno) v veno.
• Flolan must not be used chronically in patients who develop pulmonary oedema during dose ranging.
• Zdravila Flolan se ne sme kronično uporabljati pri bolnikih, ki se jim med ugotavljanjem odmerka pojavi pljučni edem.
Flolan must not be used chronically in patients who develop pulmonary edema during dose initiation (see section 4.3).
Zdravila Flolan se ne sme kronično uporabljati pri bolnikih, ki se jim med uvajanjem odmerka pojavi pljučni edem (glejte poglavje 4.3).
Chronic continuous infusions of epoprostenol in patients with PAH/SSD were studied in a prospective, open, randomised trial of 12 weeks' duration comparing epoprostenol plus conventional therapy (N = 56) to conventional therapy alone (N = 55).
Kronično stalno infundiranje epoprostenola pri bolnikih s PAH/SSD so raziskali v prospektivnem, odprtem randomiziranem 12-tedenskem preskušanju, ki je primerjalo kombinacijo epoprostenola in konvencionalnega zdravljenja (n = 56) s samim konvencionalnim zdravljenjem (n = 55).
Musculoskeletal and Connective Tissue Disorders Very common Jaw pain Common
Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti bolečina v čeljusti
There are four packs of Flolan available for use in the treatment of pulmonary arterial hypertension, the contents of each pack include:
Za zdravljenje pljučne arterijske hipertenzije so na voljo štiri pakiranja zdravila Flolan; vsako pakiranje vsebuje:
Long-term infusions should be initiated at 4 nanograms/kg/min less than the maximum tolerated infusion rate determined during short-term dose-ranging.
Dolgotrajno infundiranje je treba začeti s 4 nanogrami/kg/min manj, kot je največja tolerirana hitrost infundiranja, določena med kratkotrajnim ugotavljanjem odmerka.
Higher circulating doses of epoprostenol (20 nanograms/kg/min) disperse circulating platelet aggregates and increase by up to two fold the cutaneous bleeding time.
Višji odmerki epoprostenola v obtoku (20 nanogramov/kg/min) ločijo trombocitne agregate v obtoku in do dvakrat podaljšajo kožni čas krvavitve.
You can then be treated using an infusion pump.
Potem bo mogoče za zdravljenje uporabljati infuzijsko črpalko.
Respiratory, thoracic and mediastinal disorders Unknown
Bolezni dihal, prsnega koša in mediastinalnega prostora Ni znano pljučni edem
Twelve patients at very high risk of haemorrhage received 35 epoprostenol dialyses and 11 patients received 28 heparin dialyses in major controlled studies.
V velikih kontroliranih študijah je 12 bolnikov z zelo velikim tveganjem za krvavitev prejelo 35 dializ z epoprostenolom, 11 bolnikov pa je prejelo 28 dializ s heparinom.
This includes any possible side effects not listed in this leaflet.
Posvetujte se tudi, če katere koli opazite neželene učinke, ki niso navedeni v tem navodilu.
What you need to know before you take Flolan
Kaj morate vedeti, preden boste vzeli zdravilo Flolan Ne jemljite zdravila Flolan
The amount of sodium present in the reconstituted concentrate solution equals 55.9 mg approximately.
Količina natrija v pripravljenem koncentratu raztopine je približno 55,9 mg.
Store in the original outer carton, to protect from light.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Each vial contains 50ml solvent for parenteral use.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Ena viala vsebuje 50 ml vehikla za parenteralno uporabo.
METHOD OF ADMINISTRATION Intravenous use
POSTOPEK UPORABE intravenska uporaba
Decreased platelet count, bleeding at various sites (e.g. pulmonary, gastrointestinal, epistaxis, intracranial, post-procedural, retroperitoneal)
Bolezni krvi in limfatičnega sistema Pogosti zmanjšano število trombocitov, krvavitve na različnih mestih (npr. v pljučih, prebavilih, epistaksa, intrakranialno, po posegih, retroperitonealno)
Only the solvent supplied should be used for reconstitution of freeze-dried Flolan and only the recommended infusion solutions, in the stated ratio, should be used for further dilution, otherwise the required pH may not be maintained.
Stabilnost raztopin zdravila Flolan je odvisna od pH. Za pripravo liofiliziranega zdravila Flolan se sme uporabiti le priloženi vehikel, za nadaljnje razredčenje pa se sme uporabiti le priporočene raztopine za infundiranje v navedenem razmerju, sicer je možno, da se potrebni pH ne bo ohranil.
Where the infusion pump allows the use of a cold pouch, epoprostenol solution may be used over a 24 hour period, provided that the cold pouch is changed as necessary throughout the day.
Če infuzijska črpalka omogoča uporabo hladne vrečke, se lahko raztopino epoprostenola uporablja več kot 24 ur, pod pogojem, da se hladno vrečko tekom dneva menja, kot je potrebno.
The reconstituted solution should be examined prior to administration.
Pripravljeno raztopino je treba pred uporabo pregledati.
How to take Flolan
Kako jemati zdravilo Flolan
Examples for some concentrations commonly used in pulmonary arterial hypertension are shown below.
Spodaj so prikazane nekatere koncentracije, pogosto uporabljene pri pljučni arterijski hipertenziji.
In this case, the solutions should not be used over more than 8 hours when administered at room temperature.
V tem primeru se raztopine, ki je uporabljena pri sobni temperaturi, ne sme dajati več kot 8 ur.
During chronic therapy with Flolan the final concentration of solution may be increased by the addition of a further 0.5 mg or 1.5 mg vial of freezedried Flolan.
Med kroničnim zdravljenjem z zdravilom Flolan je lahko potrebno povečanje končne koncentracije raztopine z dodatkom še ene 0,5-mg ali 1,5-mg viale liofiliziranega zdravila Flolan.
There is only one pack available for use in renal dialysis: • One 0.5 mg powder vial and one solvent vial
Za uporabo pri ledvični dializi je na voljo le eno pakiranje: • ena viala z 0,5 mg praška in ena viala vehikla
25°C.
z -40,7 metra).
While you are being treated with Flolan your heart rate and blood pressure will be checked.
Med zdravljenjem z zdravilom Flolan vam bodo kontrolirali srčni utrip in krvni tlak.
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction and development.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti ponavljajočih odmerkih, genotoksičnosti, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
These may affect up to 1 in 10 people:
Ti se lahko pojavijo pri največ 1 od 10 oseb:
The concentrated solution is normally further diluted before use.
Koncentrirano raztopino se pred uporabo po navadi še dodatno razredči.
This medicine contains sodium: See package leaflet for further information
To zdravilo vsebuje natrij; za dodatne informacije glejte navodilo za uporabo.
Only vials of the same amount as that included in the initial starter pack may be used to increase the final concentration of solution.
Za povečanje končne koncentracije raztopine se sme uporabiti samo viale z enako količino, kot je vključena v uvodno začetno pakiranje.
• medicines used to prevent blood clots
• zdravila za preprečevanje krvnih strdkov,
A sequential stimulation of adenylate cyclase, followed by activation of phosphodiesterase, has been described in human platelets.
V človeških trombocitih je opisana zaporedna stimulacija adenilat-ciklaze, ki ji sledi aktivacija fosfodiesteraze.
This solution is now referred to as the concentrated solution and contains either 10,000 (for the 0.5 mg strength) or 30,000 nanogram per mL Flolan (for the 1.5 mg strength).
To raztopino imenujemo koncentrirana raztopina in vsebuje bodisi 10.000 (jakost 0,5 mg) bodisi 30.000 (jakost 1,5 mg) nanogramov zdravila Flolan na mililiter.
Severity of bleeding in those patients was improved more frequently with epoprostenol the day prior to dialysis and on dialysis day (predialysis: N=4/8; dialysis: N=6/16) than with heparin (predialysis: N=4/13; dialysis:
Resnost krvavitev se je pri teh bolnikih pogosteje izboljšala pri prejemnikih epoprostenola na dan pred dializo in na dan dialize (pred dializo: n = 4/8, dializa: n = 6/16) kot pri prejemnikih heparina (pred dializo: n = 4/13, dializa: n = 4/25).
Flow rates in mL/h
Hitrost pretoka v ml/h
If the initial infusion rate of 2 nanograms/kg/min is not tolerated, a lower dose which is tolerated by the patient should be identified.
Če bolnik ne prenese začetne hitrosti infundiranja 2 nanograma/kg/min, je treba najti nižji odmerek, ki ga bolnik prenese.